Overview
Goldline Pharmaceutical IPO is an SME issue that opened for subscription on 12 May 2026 and is now listed. The issue aggregates ₹11.61 Cr.
IPO Details
Goldline Pharmaceutical IPO is a Small and Medium Enterprise (SME) initial public offering scheduled to be listed on BSE SME. The issue has a price band of ₹41–₹43 per equity share with a lot size of 3000 shares, translating to a minimum retail investment of ₹1,29,000.
The issue aggregates ₹11.61 Cr, with the subscription window open from 12 May 2026 to 14 May 2026. Allotment is expected on 15 May 2026 and the equity shares are scheduled to list on 19 May 2026.
- Type
- SME
- Status
- listed
- Price band
- ₹41–₹43
- Face value
- ₹10 (typical)
- Lot size
- 3000 shares
- Min investment (Retail)
- ₹1,29,000
- Issue size
- ₹11.61 Cr
- Fresh issue
- —
- OFS
- —
- Exchange
- BSE SME
- ISIN
- TBA
- Sector
- Pharmaceuticals
Market Lot
Retail investors must apply for a minimum of one lot and can apply up to the retail cap of ₹2 lakh. NII / HNI investors apply above ₹2 lakh.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 3000 | ₹1,29,000 |
| Retail (Maximum) | 1 | 3000 | ₹1,29,000 |
| HNI / NII (Minimum) | 2 | 6000 | ₹2,58,000 |
IPO Reservation
Per SEBI guidelines, Goldline Pharmaceutical IPO reserves shares across investor categories as follows. Final allotment percentages may vary slightly based on the final issue document.
| Category | % Reserved | Notes |
|---|---|---|
| QIB | Up to 50% | Mutual funds, FIIs, banks |
| NII / HNI | Up to 15% | Bids ≥ ₹2 lakh |
| Retail | At least 35% | Bids up to ₹2 lakh |
Important Dates
- Issue Open12 May 2026 · Subscription opens
- Issue Close14 May 2026 · Subscription closes
- Allotment15 May 2026 · Basis of allotment finalised
- Refunds Initiated18 May 2026 · Funds released for non-allottees
- Listing Date19 May 2026 · Shares debut on the exchange
Grey Market Premium
Grey Market Premium for Goldline Pharmaceutical is yet to be tracked. We update GMP from multiple grey market sources during the subscription window. Bookmark this page and check IPO GMP Today for live updates.
Subscription Status
Updated —
Allotment Status
Goldline Pharmaceutical IPO allotment will be finalised by the registrar (TBA) on 15 May 2026. Check your allotment status using your PAN, application number, or DP ID via our allotment status checker or directly on the registrar's website.
If allotment fails, the blocked funds via ASBA / UPI mandate are released back within 24-48 hours. Applying through multiple demat accounts in family members' names improves chances on oversubscribed IPOs.
About Goldline Pharmaceutical
Promoter & Holding Pattern
The promoter and promoter group hold the majority stake in Goldline Pharmaceutical prior to the IPO. Post-listing, this percentage will reduce as new equity shares are issued to the public. Detailed pre-IPO and post-IPO promoter holding data will be updated once the Red Herring Prospectus is finalised with SEBI.
Objects of the Issue
The Goldline Pharmaceutical IPO proceeds will be utilised across multiple strategic objectives. Typical objects include capital expenditure for expansion, repayment of debt, general corporate purposes, working capital, and OFS by selling shareholders. Detailed breakdown with amounts will be updated here from the Red Herring Prospectus.
Financial Performance
Goldline Pharmaceutical's three-year financials — revenue, PAT, assets, net worth — will be displayed here based on audited numbers from the Red Herring Prospectus. Year-on-year growth, EBITDA margins, debt-to-equity progression, and RoNW together form the basis for valuation comparison.
Valuation Snapshot
Key valuation metrics for Goldline Pharmaceutical — RoE, RoCE, EBITDA margin, PAT margin, debt-to-equity, EPS, P/E ratio, RoNW, NAV — will be updated based on FY25 numbers from the Red Herring Prospectus.
Peer Comparison
Listed peers in the Pharmaceuticals sector with key valuation metrics:
| Company | EPS (₹) | P/E Ratio | RoNW (%) | NAV (₹) | Income (₹ Cr) |
|---|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals | — | — | — | — | — |
| Indoco Remedies | — | — | — | — | — |
Anchor Investors
Anchor investor bidding for Goldline Pharmaceutical typically opens one working day before the issue opens to the public. Anchor investors — mutual funds, FIIs, sovereign wealth funds, and insurance companies — collectively subscribe to a portion of the QIB segment. Their participation signals institutional confidence. Anchor list and total amount will be updated once SEBI publishes the anchor filing.
Lead Managers (Merchant Bankers)
Book-Running Lead Managers (BRLMs) for Goldline Pharmaceutical will be listed once confirmed in the Red Herring Prospectus. Lead managers oversee pricing, marketing, and underwriting — typically Kotak, ICICI Securities, Axis Capital, HDFC, SBI Caps, JP Morgan, or Citigroup.
IPO Registrar
The registrar for Goldline Pharmaceutical IPO will be confirmed in the Red Herring Prospectus. The registrar handles allotment, refunds, and dematerialisation of shares.
Editorial Review
How to Apply for Goldline Pharmaceutical IPO
- Open broker app — Zerodha, Upstox, Angel One, Groww, 5paisa, ICICI Direct, or any other SEBI-registered broker. Navigate to the IPO section.
- Select Goldline Pharmaceutical IPO during the bidding window (12 May 2026 – 14 May 2026).
- Enter bid details — minimum 3000 shares per lot. Retail investors are recommended to bid at cut-off price (₹43).
- Submit UPI ID linked to a SEBI-approved bank.
- Approve UPI mandate from your UPI app within the deadline. Bid amount is blocked, not debited.
- Await allotment on 15 May 2026.
- Listing day — shares list on BSE SME on 19 May 2026.